This study confirmed the efficacy of the ADC trastuzumab-deruxtecan (T-DXd) for the treatment of patients with advanced, pretreated HER2-low breast cancer; this trial is discussed in detail in this manuscript. The gene discussed is ERBB2; the disease is breast cancer.